Investor relations
Annual Report 2023
Bio-Works' 2023 Annual Report describes the company's continued journey as it positions itself as the industry's preferred "tailor" of customized solutions, while implementing significant internal changes with the aim of creating an even more agile and focused organization that is adapted to prevailing market conditions.
4 Reasons to invest in Bio-Works

An investment in Bio-Works allows participation in the expansive biotechnology sector but with a lower risk profile.

Bio-Works generates revenue in the early phases of a biotherapeutics' development, long before the approval of the drug substance.

There is a strong market demand for suppliers of chromatography resins who can offer alternatives to the few that have dominated the market for decades.

Bio-Works has the foundational cornerstones in place and is well-positioned for expansive growth without large investments in the near future.
Get the latest
Get the latest
Subscribe to press releases and reports via email.
Check the types of releases you want to subscribe to.
Contact - Investor relations
Investor relations
Arne Hauge
Chief Financial Officer, Bio-Works Technologies
Phone: +46(0)8-502 705 83
Email: arne.hauge@bio-works.com
Stock Information
Bio-Works’ stock is listed on the Spotlight Stock Market where it is traded under the ticker BIOWKS. The ISIN code for the stock is SE0007387089.
See the current price for Bio-Works' (BIOWKS) on the Spotlight Stock Market.